You are viewing an expired study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Minneapolis, Minnesota 55455

  • Multiple Myeloma

Purpose:

The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.


Study summary:

Preparative regimen using total body irradiation (TBI) and cyclophosphamide: 1. on day -6 and -5: cyclophosphamide is given, 2. on day -4, -3, -2, and -1: TBI is given, 3. on day 0: stem cell or bone marrow is infused. Alternate preparative therapy for patients not able to receive TBI The chemotherapy (cyclophosphamide and busulfan) is given with the intent of destroying the bone marrow, eliminating any cancerous and preparing for the transplant of the donor's blood stem cells by suppressing the immune system. l. Ten days before the transplant (Day 10), subjects will be admitted to the bone marrow transplant unit and placed in isolation to reduce exposure to infections. Isolation will be continued until adequate numbers of cells are present in the blood to fight infection. 2. On day -9, -8, -7, -6 busulfan is given. 3. On day -5, -4, -3, -2 cyclophosphamide is given. 4. On day -1 no therapy is given (day of rest). 5. On day 0 the donor stem cells are given intravenously. Additional cells may be given on day +1 or 2 as needed. Transplant: Subjects will be admitted to the bone marrow transplant unit and put in isolation to reduce exposure to infectious agents. During this time, they will receive the preparative treatment outlined above. Once they have received the preparative regimen, stem cells will be obtained from the donor and given intravenously. The new stem cells will replace the bone marrow that was damaged by the treatment for the cancer. Isolation will be continued until adequate numbers of cells are present in the blood to fight infection. Subjects will then be transferred from the bone marrow transplant unit and discharged from the hospital when medically ready. Subjects will be expected to return for follow-up to the bone marrow transplant clinic at specific dates as determined by their physician.


Criteria:

Inclusion Criteria: - Donor will be <75 years of age and in good health. - Recipients will be < or = 55 years, will have normal organ function (excluding bone marrow) and will have a Karnofsky activity assessment > or = 90%. - Recipients with related or unrelated donor matched at the HLA A, B, DRB1 loci, or mismatched related or unrelated (if < 35 years old) at a single HLA A, B, DRB1 locus. - Recipients will be eligible in one of the following disease categories - Chronic myelogenous leukemia in accelerated phase or in post blast crisis second or greater chronic phase; or in chronic phase but intolerant of or resistant to tyrosine kinase inhibitors. - Acute myelocytic leukemia in first or greater remission, or first, second or third relapse. - Acute lymphocytic leukemia in the 2nd or greater bone marrow remission. - High risk children will be transplanted in first remission if they meet criteria - Myelodysplastic syndrome. - Myeloproliferative Diseases - (i.e. myelofibrosis, chronic myelomonocytic leukemia (CMML)) - Juvenile myelomonocytic leukemia - Chronic lymphocytic leukemia - Advanced non-Hodgkin's (NHL). - Advanced Hodgkin's disease beyond PR2 (> CR3, > PR3). - Multiple Myeloma after initial therapy. - Donors and recipients signed informed consent Exclusion Criteria donors and recipients should meet the following test criteria. - required for donors: - anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-priming. - CBC, platelet count each day of apheresis, day 0 (or 1 or 2 as needed) - required for recipients: - anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-transplant.


NCT ID:

NCT00176930


Primary Contact:

Principal Investigator
Daniel Weisdorf, MD
Masonic Cancer Center, University of Minnesota


Backup Contact:

N/A


Location Contact:

Minneapolis, Minnesota 55455
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.